CASI Shares Outstanding History
Below is a table of the CASI shares outstanding history going back to 7/1/2010:

Date CASI Shares Outstanding
7/1/2010922659
8/4/2010962977
11/10/20101.15M
3/23/20111.15M
5/12/20111.16M
8/8/20111.22M
11/8/20111.22M
3/1/20121.22M
5/10/20122.25M
8/8/20122.25M
11/8/20122.25M
3/14/20132.70M
5/10/20132.70M
8/9/20132.70M
11/8/20132.70M
3/14/20142.70M
5/8/20142.70M
8/8/20142.70M
11/7/20143.24M
3/18/20153.24M
5/8/20153.24M
8/7/20153.24M
11/6/20153.24M
3/18/20164.26M
5/6/20164.26M
8/8/20164.95M
11/7/20166.02M
3/22/20176.02M
5/5/20176.02M
8/4/20176.02M
11/6/20176.51M
3/28/20187.96M
5/8/20188.61M
8/8/20188.66M
11/7/20189.36M
3/25/20199.57M
5/8/20199.57M
8/2/20199.57M
10/3/20179.35M
11/6/20199.63M
3/11/20209.90M
5/5/202010.09M
8/6/202012.39M
11/6/202012.39M
3/26/202113.98M
4/28/202113.98M
4/30/202113.98M
8/10/202113.98M
11/8/202113.98M
3/18/202213.66M
5/6/202213.61M
8/5/202213.61M

Also see: CASI Market Cap History
CASI YTD Return
CASI Historical Shares Outstanding:
+24.90% CAGR
CASI Historical Shares Outstanding: +24.90% CAGR

Mouse over chart for data details
7/1/2010 ...8/5/2022
CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, the U.S., and throughout the world.. In China, Co.'s first commercial product, EVOMELA® is approved for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The other core hematology/oncology assets in our pipeline include: CNCT19, which is being developed as a potential treatment for patients with hematological malignancies which express CD19 including, B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. We show 52 historical shares outstanding datapoints in our coverage of CASI's shares outstanding history.

Understanding the changing numbers of CASI shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like CASI versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching CASI by allowing them to research CASI shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree CASI Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
CASI Pharmaceuticals (CASI) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

CASM Shares Outstanding History
CATB Shares Outstanding History
CATS Shares Outstanding History
CBAY Shares Outstanding History
CBIO Shares Outstanding History
CBLI Shares Outstanding History
CBM Shares Outstanding History
CBMG Shares Outstanding History
CBPO Shares Outstanding History
CCCC Shares Outstanding History
More Healthcare companies »

 

CASI Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2022, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.